Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice
Journal of Virology · 2026
DOI: 10.1128/jvi.01774-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2026. Verfasst von Juan García-Bernalt Diego und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Pneumococcal Infections, Influenza Vaccines, Orthomyxoviridae Infections, Coinfection. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Ministerio de Ciencia e Innovación.
Abstract (Originalsprache)
Secondary bacterial infections can significantly worsen the clinical course of influenza virus infections and are a leading cause of morbidity and mortality during seasonal influenza epidemics. Despite being a vaccine-preventable disease, influenza-related complications from secondary bacterial infections are an important cause of death, particularly among the elderly population. Streptococcus pneumoniae (Spn) is the most common agent responsible for influenza-related secondary bacterial infections. Influenza virus vaccination serves as an effective prophylactic strategy for preventing influenza and reducing the burden of influenza-associated pathology, including secondary bacterial infection. However, whether the protective effects of influenza virus vaccination differ in the context of a secondary Spn infection at the level of the host response remains poorly characterized. Here, we present a preclinical mouse model to examine the impact of influenza vaccination in scenarios involving single infections with influenza A virus H1N1 (NC99) or Spn serotype 1; simultaneous infection with both NC99 and Spn (coinfection), or NC99 infection followed by Spn infection seven days later (superinfection). A single dose of trivalent inactivated Influenza vaccine (TIV) is able to decrease infection lethality in both secondary bacterial infection scenarios. Protection is associated with reduction in both viral and bacterial titers, decreased production of pro-inflammatory cytokines, protection of alveolar macrophages, prevention of exacerbated lung neutrophil recruitment, modulation of neutrophil activation status, and induction of lung eosinophil recruitment and activation. These findings underscore the importance of influenza vaccination in modulating disease progression and preventing morbidity and mortality associated with secondary bacterial infections. IMPORTANCE In this study, we show that a licensed influenza vaccine not only prevents severe disease upon influenza virus infection but also helps protect against enhanced morbidity due to co- or superinfection with S treptococcus pneumoniae in a mouse model. This protection correlates with better control of viral and bacterial titers, as well as with altered host immune responses during bacterial co- and superinfection, characterized by the recruitment of activated granulocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Microbiology Section, Dpto. CC, Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.
- Institute of Applied Molecular Medicine-Nemesio Díez (IMMA-ND), Department of Basic Medical Sciences, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Madrid, Spain.
- National Microbiology Center, National Institutes of Health Carlos III, Madrid, Spain.
- Department of Pharmaceutics, Ghent University, Ghent, Belgium.
ORCID-Profile: Juan García-Bernalt Diego, Javier Arranz-Herrero, Lauren A Chang, Jordi Ochando, Estanislao Nistal-Villan, Michael Schotsaert
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Ministerio de Ciencia e Innovación
Zitieren
APA
Diego, J. G. B., Arranz-Herrero, J., Laghlali, G., Burgess, E., Park, S. C., Singh, G., Chang, L. A., Warang, P., Noureddine, M., Ochando, J., Nistal-Villan, E., & Schotsaert, M. (2026). Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice. Journal of Virology. https://doi.org/10.1128/jvi.01774-25
Vancouver
Diego JGB, Arranz-Herrero J, Laghlali G, Burgess E, Park SC, Singh G, et al. Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice. Journal of Virology. 2026. doi:10.1128/jvi.01774-25
BibTeX
@article{Diego2026,
author = {Diego, Juan García-Bernalt and Arranz-Herrero, Javier and Laghlali, Gabriel and Burgess, Eleanor and Park, Seok-Chan and Singh, Gagandeep and Chang, Lauren A and Warang, Prajakta and Noureddine, Moataz and Ochando, Jordi and Nistal-Villan, Estanislao and Schotsaert, Michael},
title = {Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice},
journal = {Journal of Virology},
year = {2026},
doi = {10.1128/jvi.01774-25}
}
EUVIMED